Diagnostic Direct-To-Consumer Ads Will Increase With Rx Therapies – Root
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic manufacturers increasingly will rely on patient-driven reimbursement strategies as diagnostic tests are used more frequently to determine appropriate drug therapy, according to consultant Charles Root, MCF Compliance president
You may also be interested in...
CDRH Promotion & Advertising Website Planned; DTC Guidance In Works
Device untitled letters could be easier to access in the coming months, once CDRH's planned promotion and advertising policy staff (PAPS) website is developed
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.